The firm has a market cap of $35.63 million, a P/E ratio of -1.03 and a beta of 0.41. CASI Pharmaceuticals has a 1 year low of $2.04 and a 1 year high of $7.67. An institutional investor recently ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MIRA Pharmaceuticals (MIRA) announced that it has signed a binding letter of intent or LOI to acquire SKNY Pharmaceuticals… The transaction ...

MIRA Pharmaceuticals (MIRA) has signed a binding letter of intent to acquire SKNY Pharmaceuticals. The transaction includes a $5M capital ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

All dollar values are in U.S. dollars unless stated otherwise. Eupraxia Pharmaceuticals logo (CNW Group/Eupraxia Pharmaceuticals Inc.) On October 2, 2024, the Company announced the appointment of ...